PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16799062-3	2006	This study was conducted to examine the effect of the dipeptide arginyl-glutamine (Arg-Gln) on vascular endothelial cell growth factor (VEGF) levels in primary human retinal pigment epithelial (hRPE) cell cultures and on inhibition of neovascularization in the oxygen-induced retinopathy (OIR) model.	arginyl-glutamine	64-81	vascular endothelial growth factor A	Homo sapiens	136-140
22020559-10	2012	Supplementation of Arg-Gln or DHA reduced hyperoxia-induced MPO activity (P<0.05).	arginyl-glutamine	19-26	myeloperoxidase	Mus musculus	60-63
16799062-3	2006	This study was conducted to examine the effect of the dipeptide arginyl-glutamine (Arg-Gln) on vascular endothelial cell growth factor (VEGF) levels in primary human retinal pigment epithelial (hRPE) cell cultures and on inhibition of neovascularization in the oxygen-induced retinopathy (OIR) model.	arginyl-glutamine	83-90	vascular endothelial growth factor A	Homo sapiens	136-140
16799062-4	2006	METHODS: The effects of Arg-Gln on VEGF levels were measured in supernates from hRPE cells by using ELISAs.	arginyl-glutamine	24-31	vascular endothelial growth factor A	Homo sapiens	35-39
16799062-10	2006	In the OIR model, Arg-Gln at 5 g/kg per day reduced preretinal neovascularization by 82%+/-7% (P<0.005), when compared with the control dipeptide Ala-Gly, and reduced VEGF mRNA by 64%+/-9% (P<0.001).	arginyl-glutamine	18-25	vascular endothelial growth factor A	Homo sapiens	170-174
31904876-1	2020	OBJECTIVES/HYPOTHESIS: Glutamine metabolism is a critical energy source for iatrogenic laryngotracheal stenosis (iLTS) scar fibroblasts, and glutaminase (GLS) is an essential enzyme converting glutamine to glutamate.	arginyl-glutamine	23-32	glutaminase	Homo sapiens	154-157
303241-5	1977	Its amino acid composition and apparent molecular weight estimated by Sephadex G-25 chromatography, indicate that FTS is a nonapeptide of composition lysine, aspartic acid (or asparagine), serine 2, glutamic acid (or glutamine) 2, glycine 2, and alanine.	arginyl-glutamine	217-226	AKT interacting protein	Homo sapiens	114-117
290994-10	1979	Intracellular pool measurements and systematic alteration of perfusate amino acid composition indicated that the autophagic and proteolytic effects of glucagon are mediated by a hormonally induced depletion of glycine, alanine, glutamate, and glutamine; of these, glutamine alone is the most effective.	arginyl-glutamine	243-252	glucagon	Rattus norvegicus	151-159
290994-10	1979	Intracellular pool measurements and systematic alteration of perfusate amino acid composition indicated that the autophagic and proteolytic effects of glucagon are mediated by a hormonally induced depletion of glycine, alanine, glutamate, and glutamine; of these, glutamine alone is the most effective.	arginyl-glutamine	264-273	glucagon	Rattus norvegicus	151-159
31904876-1	2020	OBJECTIVES/HYPOTHESIS: Glutamine metabolism is a critical energy source for iatrogenic laryngotracheal stenosis (iLTS) scar fibroblasts, and glutaminase (GLS) is an essential enzyme converting glutamine to glutamate.	arginyl-glutamine	193-202	glutaminase	Homo sapiens	141-152
31904876-1	2020	OBJECTIVES/HYPOTHESIS: Glutamine metabolism is a critical energy source for iatrogenic laryngotracheal stenosis (iLTS) scar fibroblasts, and glutaminase (GLS) is an essential enzyme converting glutamine to glutamate.	arginyl-glutamine	193-202	glutaminase	Homo sapiens	154-157
31898404-3	2020	Here, we first asked whether mice with a homozygous deletion of Glud1 in CNS (CNS-Glud1-/- mice) express different levels of glutamate in hippocampus, and found elevated glutamate as well as glutamine in dorsal and ventral hippocampus, and increased glutamine in medial prefrontal cortex.	arginyl-glutamine	191-200	glutamate dehydrogenase 1	Mus musculus	64-69
32061735-1	2020	The transglutaminase (TGase) family consists of eight isozymes that catalyze the Ca2+-dependent crosslink formation between the glutamine and lysine residues of proteins.	arginyl-glutamine	128-137	transglutaminase 1	Homo sapiens	4-20
32061735-1	2020	The transglutaminase (TGase) family consists of eight isozymes that catalyze the Ca2+-dependent crosslink formation between the glutamine and lysine residues of proteins.	arginyl-glutamine	128-137	transglutaminase 1	Homo sapiens	22-27
31705891-6	2020	Hippocampal slices from GFAP-LepR-/- mice displayed lower Glu uptake efficacy together with up-regulation of GLT-1, glutamine synthase, GFAP and GLUT-1.	arginyl-glutamine	116-125	glial fibrillary acidic protein	Mus musculus	24-28
31705891-6	2020	Hippocampal slices from GFAP-LepR-/- mice displayed lower Glu uptake efficacy together with up-regulation of GLT-1, glutamine synthase, GFAP and GLUT-1.	arginyl-glutamine	116-125	leptin receptor	Mus musculus	29-33
31649131-5	2020	Oxidative phosphorylation (OXPHOS) in Evi1/MF9 AML cells accelerated prior to activation of glycolysis, with a higher dependency on glutamine as an energy source.	arginyl-glutamine	132-141	MDS1 and EVI1 complex locus	Homo sapiens	38-42
31649131-7	2020	L-asparaginase (L-asp) exacerbated growth inhibition induced by glutamine starvation and suppressed OXPHOS and proliferation of Evi1/MF9 both in vitro and in vivo; high sensitivity to L-asp was caused by low expression of asparagine synthetase (ASNS) and L-asp-induced suppression of glutamine metabolism.	arginyl-glutamine	64-73	asparaginase and isoaspartyl peptidase 1	Homo sapiens	0-14
31649131-7	2020	L-asparaginase (L-asp) exacerbated growth inhibition induced by glutamine starvation and suppressed OXPHOS and proliferation of Evi1/MF9 both in vitro and in vivo; high sensitivity to L-asp was caused by low expression of asparagine synthetase (ASNS) and L-asp-induced suppression of glutamine metabolism.	arginyl-glutamine	284-293	asparaginase and isoaspartyl peptidase 1	Homo sapiens	0-14
31898404-3	2020	Here, we first asked whether mice with a homozygous deletion of Glud1 in CNS (CNS-Glud1-/- mice) express different levels of glutamate in hippocampus, and found elevated glutamate as well as glutamine in dorsal and ventral hippocampus, and increased glutamine in medial prefrontal cortex.	arginyl-glutamine	250-259	glutamate dehydrogenase 1	Mus musculus	64-69
31899205-8	2020	Mechanistically, OGDHL downregulation upregulated the alpha-ketoglutarate (alphaKG):citrate ratio by reducing OGDHC activity, which subsequently drove reductive carboxylation (RC) of glutamine-derived alphaKG for lipogenesis via retrograde TCA cycling in hepatoma cells.	arginyl-glutamine	183-192	oxoglutarate dehydrogenase L	Homo sapiens	17-22
31630411-11	2020	In addition, baseline levels of four amino acids (ie, glutamate, glutamine, threonine, and glycine) and two organic acids (ie, lactate and citric acid) were significantly different in ILK knockdown compared with wild-type HPDLFs.	arginyl-glutamine	65-74	integrin linked kinase	Homo sapiens	184-187
31911550-5	2020	NRF2 activation metabolically rewired and elevated pathways involved in glutamine metabolism.	arginyl-glutamine	72-81	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
32016368-3	2020	To understand system responses to aaRS depletion, the yeast glutamine aaRS gene (GLN4) was transcriptionally regulated using doxycycline by tet-off control.	arginyl-glutamine	60-69	alanyl-tRNA synthetase 1	Homo sapiens	34-38
32016368-3	2020	To understand system responses to aaRS depletion, the yeast glutamine aaRS gene (GLN4) was transcriptionally regulated using doxycycline by tet-off control.	arginyl-glutamine	60-69	alanyl-tRNA synthetase 1	Homo sapiens	70-74
32016368-3	2020	To understand system responses to aaRS depletion, the yeast glutamine aaRS gene (GLN4) was transcriptionally regulated using doxycycline by tet-off control.	arginyl-glutamine	60-69	glutamine--tRNA ligase	Saccharomyces cerevisiae S288C	81-85
31899205-0	2020	OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.	arginyl-glutamine	67-76	oxoglutarate dehydrogenase L	Homo sapiens	0-5
31899205-11	2020	The reduction of reductive glutamine metabolism through OGDHL overexpression or through use of glutaminase inhibitors sensitized tumor cells to sorafenib, a molecular-targeted therapy for HCC.	arginyl-glutamine	27-36	oxoglutarate dehydrogenase L	Homo sapiens	56-61
31899205-12	2020	CONCLUSION: Our findings established that silencing of OGDHL contributed to HCC development and survival by regulating glutamine metabolic pathways, and suggest OGDHL as a promising prognostic biomarker and therapeutic target for HCC.	arginyl-glutamine	119-128	oxoglutarate dehydrogenase L	Homo sapiens	55-60
31965176-5	2020	Glutamine promotes mTORC1 activation via Arf1 independently of the Rag GTPase.	arginyl-glutamine	0-9	CREB regulated transcription coactivator 1	Mus musculus	19-25
31965176-5	2020	Glutamine promotes mTORC1 activation via Arf1 independently of the Rag GTPase.	arginyl-glutamine	0-9	ADP ribosylation factor 1	Homo sapiens	41-45
31630411-13	2020	Among them, four amino acids (ie, glutamate, glutamine, threonine, and glycine) and two organic acids (ie, lactate and citric acid) may be closely linked to ILK.	arginyl-glutamine	45-54	integrin linked kinase	Homo sapiens	157-160
31830361-6	2020	The 1.38 A crystal structure of the CypA/PreNAC complex displays a contact between alanine 53 of  alpha -synuclein and glutamine 111 in the catalytic pocket of CypA.	arginyl-glutamine	119-128	peptidylprolyl isomerase A	Homo sapiens	36-40
32034306-0	2020	EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma.	arginyl-glutamine	45-54	epidermal growth factor receptor	Homo sapiens	0-4
32034306-0	2020	EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma.	arginyl-glutamine	45-54	glutamate dehydrogenase 1	Homo sapiens	15-19
32034306-0	2020	EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma.	arginyl-glutamine	45-54	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
32034306-0	2020	EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma.	arginyl-glutamine	45-54	mitogen-activated protein kinase 1	Homo sapiens	78-81
32034306-0	2020	EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma.	arginyl-glutamine	45-54	ETS transcription factor ELK1	Homo sapiens	82-86
32034306-4	2020	In this study, we found that glutamine metabolism was upregulated after EGFR activation in a GDH1 (glutamate dehydrogenase 1)-dependent manner.	arginyl-glutamine	29-38	epidermal growth factor receptor	Homo sapiens	72-76
32034306-4	2020	In this study, we found that glutamine metabolism was upregulated after EGFR activation in a GDH1 (glutamate dehydrogenase 1)-dependent manner.	arginyl-glutamine	29-38	glutamate dehydrogenase 1	Homo sapiens	93-97
32034306-4	2020	In this study, we found that glutamine metabolism was upregulated after EGFR activation in a GDH1 (glutamate dehydrogenase 1)-dependent manner.	arginyl-glutamine	29-38	glutamate dehydrogenase 1	Homo sapiens	99-124
32034306-8	2020	Phosphorylated ELK1 enriched in the promoter of GDH1 to activate the transcription of GDH1, which then promoted glutamine metabolism.	arginyl-glutamine	112-121	ETS transcription factor ELK1	Homo sapiens	15-19
32034306-8	2020	Phosphorylated ELK1 enriched in the promoter of GDH1 to activate the transcription of GDH1, which then promoted glutamine metabolism.	arginyl-glutamine	112-121	glutamate dehydrogenase 1	Homo sapiens	48-52
32034306-8	2020	Phosphorylated ELK1 enriched in the promoter of GDH1 to activate the transcription of GDH1, which then promoted glutamine metabolism.	arginyl-glutamine	112-121	glutamate dehydrogenase 1	Homo sapiens	86-90
32034306-10	2020	Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	arginyl-glutamine	193-202	epidermal growth factor receptor	Homo sapiens	41-45
32034306-10	2020	Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	arginyl-glutamine	193-202	ETS transcription factor ELK1	Homo sapiens	61-65
32034306-10	2020	Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	arginyl-glutamine	193-202	glutamate dehydrogenase 1	Homo sapiens	78-82
32034306-10	2020	Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	arginyl-glutamine	193-202	mitogen-activated protein kinase kinase 7	Homo sapiens	124-127
32034306-10	2020	Collectively, our findings indicate that EGFR phosphorylates ELK1 to activate GDH1 transcription and glutaminolysis through MEK/ERK pathway, providing new insight into oncogenic alterations of glutamine metabolism.	arginyl-glutamine	193-202	mitogen-activated protein kinase 1	Homo sapiens	128-131
31830361-6	2020	The 1.38 A crystal structure of the CypA/PreNAC complex displays a contact between alanine 53 of  alpha -synuclein and glutamine 111 in the catalytic pocket of CypA.	arginyl-glutamine	119-128	peptidylprolyl isomerase A	Homo sapiens	160-164
31866442-0	2020	A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.	arginyl-glutamine	39-48	solute carrier family 1 member 5	Homo sapiens	13-19
31883789-5	2020	Searching for the underlying metabolic basis, we find that BP expansion by ARHGAP11B requires glutaminolysis, the conversion of glutamine to glutamate for the tricarboxylic acid (TCA) cycle.	arginyl-glutamine	128-137	Rho GTPase activating protein 11B	Homo sapiens	75-84
31596504-3	2020	Glutaminase isoenzymes (GLS and GLS2) are key enzymes for glutamine metabolism.	arginyl-glutamine	58-67	glutaminase 2	Homo sapiens	32-36
31556966-5	2020	A new inhibition mechanism was evidenced for the second Kunitz domain of GASP-2, in which the conventional cationic residue of trypsin inhibitors was substituted by the strongly interacting glutamine residue.	arginyl-glutamine	190-199	WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1	Homo sapiens	73-79
31990147-8	2020	The inhibition of ASCT2 reduced the glutamine-related biomarkers and augmented the apoptotic process.	arginyl-glutamine	36-45	solute carrier family 1 member 5	Homo sapiens	18-23
31990147-12	2020	In conclusion, the present work suggested that Lobetyolin could induce the apoptosis via the inhibition of ASCT2-mediated glutamine metabolism, which was possibly governed by p53.	arginyl-glutamine	122-131	solute carrier family 1 (neutral amino acid transporter), member 5	Mus musculus	107-112
31990147-12	2020	In conclusion, the present work suggested that Lobetyolin could induce the apoptosis via the inhibition of ASCT2-mediated glutamine metabolism, which was possibly governed by p53.	arginyl-glutamine	122-131	transformation related protein 53, pseudogene	Mus musculus	175-178
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	transglutaminase 2	Homo sapiens	26-29
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	eukaryotic translation initiation factor 4E	Homo sapiens	43-86
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	eukaryotic translation initiation factor 4E	Homo sapiens	101-144
32034133-5	2020	It also provides the first evidence that in addition to promoting tumor growth and metastasis in vivo, KISS1R-induced glutamine dependence of tumors.	arginyl-glutamine	118-127	KISS1 receptor	Homo sapiens	103-109
32034133-6	2020	In addition, tracer-based metabolomics analyses revealed that KISS1R promoted glutaminolysis and nucleotide biosynthesis by increasing c-Myc and glutaminase levels, key regulators of glutamine metabolism.	arginyl-glutamine	183-192	KISS1 receptor	Homo sapiens	62-68
32034133-6	2020	In addition, tracer-based metabolomics analyses revealed that KISS1R promoted glutaminolysis and nucleotide biosynthesis by increasing c-Myc and glutaminase levels, key regulators of glutamine metabolism.	arginyl-glutamine	183-192	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	135-140
31866442-3	2020	Here, we show that the SLC1A5 variant plays a critical role in cancer metabolic reprogramming by transporting glutamine into mitochondria.	arginyl-glutamine	110-119	solute carrier family 1 member 5	Homo sapiens	23-29
31866442-6	2020	Overexpression of the SLC1A5 variant mediates glutamine-induced ATP production and glutathione synthesis and confers gemcitabine resistance to pancreatic cancer cells.	arginyl-glutamine	46-55	solute carrier family 1 member 5	Homo sapiens	22-28
31866442-8	2020	This work demonstrates that the SLC1A5 variant is a mitochondrial glutamine transporter for cancer metabolic reprogramming.	arginyl-glutamine	66-75	solute carrier family 1 member 5	Homo sapiens	32-38
31661467-3	2020	This pathway is glutamine dependent and triggered by binding of beta1-integrin to VCAM-1 on neurons in inflammatory context.	arginyl-glutamine	16-25	integrin subunit beta 1	Homo sapiens	64-78
31661467-3	2020	This pathway is glutamine dependent and triggered by binding of beta1-integrin to VCAM-1 on neurons in inflammatory context.	arginyl-glutamine	16-25	vascular cell adhesion molecule 1	Homo sapiens	82-88
32069221-0	2020	Glutamine metabolism in the proliferation of GS-expression pituitary tumor cells.	arginyl-glutamine	0-9	glutamate-ammonia ligase	Homo sapiens	45-47
32069221-12	2020	CONCLUSIONS: Our data indicate that GS is needed for PA cells to proliferation during Gln deprivation, and most human PA cells express GS and might have a negative response to exogenous Gln depletion.	arginyl-glutamine	86-89	glutamate-ammonia ligase	Homo sapiens	36-38
31899225-15	2020	Interestingly, glutamine supplementation ameliorates cadmium-induced testicular dysfunction through enhancement of G6PD activity.	arginyl-glutamine	15-24	glucose-6-phosphate dehydrogenase	Rattus norvegicus	115-119
31870500-5	2020	In contrast, the expression of key proteins involved in ammonia metabolism and secretion by proximal cells, namely the glutamine transporter SNAT3, the phosphate-dependent glutaminase and phosphoenolpyruvate carboxykinase enzymes, and the sodium-proton exchanger NHE-3 was inappropriate in Kcnj15-deleted mice.	arginyl-glutamine	119-128	solute carrier family 38, member 3	Mus musculus	141-146
31760230-0	2020	DHA and its derived lipid mediators MaR1, RvD1 and RvD2 block TNF-alpha inhibition of intestinal sugar and glutamine uptake in Caco-2 cells.	arginyl-glutamine	107-116	retrotransposon Gag like 1	Homo sapiens	36-40
31760230-0	2020	DHA and its derived lipid mediators MaR1, RvD1 and RvD2 block TNF-alpha inhibition of intestinal sugar and glutamine uptake in Caco-2 cells.	arginyl-glutamine	107-116	tumor necrosis factor	Homo sapiens	62-71
31760230-4	2020	Here, we investigated whether the n3-PUFA DHA and its derived specialized pro-resolving lipid mediators (SPMs) MaR1, RvD1 and RvD2, could block TNF-alpha inhibition of intestinal sugar and glutamine uptake.	arginyl-glutamine	189-198	pumilio RNA binding family member 3	Homo sapiens	37-41
31760230-4	2020	Here, we investigated whether the n3-PUFA DHA and its derived specialized pro-resolving lipid mediators (SPMs) MaR1, RvD1 and RvD2, could block TNF-alpha inhibition of intestinal sugar and glutamine uptake.	arginyl-glutamine	189-198	retrotransposon Gag like 1	Homo sapiens	111-115
31760230-4	2020	Here, we investigated whether the n3-PUFA DHA and its derived specialized pro-resolving lipid mediators (SPMs) MaR1, RvD1 and RvD2, could block TNF-alpha inhibition of intestinal sugar and glutamine uptake.	arginyl-glutamine	189-198	tumor necrosis factor	Homo sapiens	144-153
31760230-9	2020	In Caco-2 cells, TNF-alpha also inhibited glutamine uptake being this inhibition prevented by EPA, DHA and the DHA-derived SPMs.	arginyl-glutamine	42-51	tumor necrosis factor	Homo sapiens	17-26
31760230-10	2020	Interestingly, TNF-alpha increased the expression in the apical membrane of the glutamine transporter B0AT1.	arginyl-glutamine	80-89	tumor necrosis factor	Homo sapiens	15-24
31760230-10	2020	Interestingly, TNF-alpha increased the expression in the apical membrane of the glutamine transporter B0AT1.	arginyl-glutamine	80-89	solute carrier family 6 member 19	Homo sapiens	102-107
31871054-6	2020	Comparison of glutamine binding in the presence or absence of the BPTES analog CB-839 revealed a reciprocal relationship between the constraints imposed on the activation loop position and the affinity of GAC for substrate.	arginyl-glutamine	14-23	glutaminase	Homo sapiens	205-208
31743809-6	2020	Two hours after exercise, interleukin (IL)-1beta decreased compared with post-exercise in placebo and was lower compared with baseline in the CHO + Gln condition.	arginyl-glutamine	148-151	interleukin 1 beta	Homo sapiens	26-48
31743809-7	2020	Tumor necrosis factor-alpha decreased 2 h after exercise compared with baseline and pre-exercise in the CHO + Gln condition.	arginyl-glutamine	110-113	tumor necrosis factor	Homo sapiens	0-27
31743809-12	2020	CONCLUSIONS: Gln supplementation for 6 d before exercise, associated with CHO supplementation during exercise, was able to revert Gln reduction after exercise and after 2 h of recovery and may have contributed to reducing tumor necrosis factor-alpha production, suggesting a possible anti-inflammatory effect of supplementation.	arginyl-glutamine	13-16	tumor necrosis factor	Homo sapiens	222-249
31930351-4	2020	This approach identified three RNA-binding proteins: the Tudor-Staphylococcal Nuclease Domain 1 (SND1) protein and two proteins from the Drosophila behavior human splicing family, the ParaSpeckle Protein Component 1 and the Splicing Factor Proline- and Glutamine- rich protein.	arginyl-glutamine	253-262	Tudor staphylococcal nuclease	Drosophila melanogaster	97-101
31871054-7	2020	Binding of the inhibitor weakened the affinity of GAC for glutamine, whereas activating anions such as inorganic phosphate increased this affinity.	arginyl-glutamine	58-67	glutaminase	Homo sapiens	50-53
31991105-6	2020	Diapause furthermore activates expression of glutamine transporters SLC38A1/2.	arginyl-glutamine	45-54	solute carrier family 38, member 1	Mus musculus	68-77
31987035-5	2020	RESULTS: We show that the disruption of the gene for TRAP1 in a panel of cell lines dysregulates OXPHOS by a metabolic rewiring that induces the anaplerotic utilization of glutamine metabolism to replenish TCA cycle intermediates.	arginyl-glutamine	172-181	TNF receptor associated protein 1	Homo sapiens	53-58
31998641-1	2019	Asparagine Synthetase (ASNS) catalyzes the synthesis of the non-essential amino acid asparagine (Asn) from aspartate (Asp) and glutamine (Gln).	arginyl-glutamine	127-136	asparagine synthetase (glutamine-hydrolyzing)	Homo sapiens	0-21
31959741-0	2020	NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter.	arginyl-glutamine	72-81	neural precursor cell expressed, developmentally down-regulated gene 4-like	Mus musculus	0-6
31959741-8	2020	In addition to ULK1, ASCT2, a glutamine transporter, was accumulated in NEDD4L-depleted cells; this is important for maintaining autophagy activation and mitochondrial metabolic function.	arginyl-glutamine	30-39	solute carrier family 1 (neutral amino acid transporter), member 5	Mus musculus	21-26
31959741-8	2020	In addition to ULK1, ASCT2, a glutamine transporter, was accumulated in NEDD4L-depleted cells; this is important for maintaining autophagy activation and mitochondrial metabolic function.	arginyl-glutamine	30-39	neural precursor cell expressed, developmentally down-regulated gene 4-like	Mus musculus	72-78
31980651-6	2020	STS subtypes expressing elevated glutaminase (GLS) levels are highly sensitive to glutamine starvation.	arginyl-glutamine	82-91	glutaminase	Homo sapiens	33-44
31980651-6	2020	STS subtypes expressing elevated glutaminase (GLS) levels are highly sensitive to glutamine starvation.	arginyl-glutamine	82-91	glutaminase	Homo sapiens	46-49
31942023-7	2020	In TGF-beta-treated PASMCs, glucose, glutamine and fatty acids all contributed carbons to the TCA cycle.	arginyl-glutamine	37-46	transforming growth factor beta 1	Homo sapiens	3-11
31919076-0	2021	WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.	arginyl-glutamine	24-33	WEE1 G2 checkpoint kinase	Homo sapiens	0-4
31998641-1	2019	Asparagine Synthetase (ASNS) catalyzes the synthesis of the non-essential amino acid asparagine (Asn) from aspartate (Asp) and glutamine (Gln).	arginyl-glutamine	127-136	asparagine synthetase (glutamine-hydrolyzing)	Homo sapiens	23-27
31998641-1	2019	Asparagine Synthetase (ASNS) catalyzes the synthesis of the non-essential amino acid asparagine (Asn) from aspartate (Asp) and glutamine (Gln).	arginyl-glutamine	138-141	asparagine synthetase (glutamine-hydrolyzing)	Homo sapiens	0-21
31998641-1	2019	Asparagine Synthetase (ASNS) catalyzes the synthesis of the non-essential amino acid asparagine (Asn) from aspartate (Asp) and glutamine (Gln).	arginyl-glutamine	138-141	asparagine synthetase (glutamine-hydrolyzing)	Homo sapiens	23-27
32021853-4	2020	CPS1 downregulation is thought to play a role in hepatocarcinogenesis through an increased glutamine availability for de novo pyrimidine biosynthesis, which CAD catalyzes the first three steps for.	arginyl-glutamine	91-100	carbamoyl-phosphate synthase 1	Homo sapiens	0-4
31911602-3	2020	Here we show that the Homo sapiens NAD+ synthetase (hsNadE) lacks substrate specificity for glutamine over ammonia and displays a modest activation of the glutaminase domain compared to tbNadE.	arginyl-glutamine	92-101	NAD synthetase 1	Homo sapiens	35-50
31638822-7	2020	All the peptides formed cyclo-derivatives, and only specific glutamine residues were involved in the cycle formation and reacted with monodansyl-cadaverine: Q29 of P-H, Q37 of P-D, Q21 of II-2, Q41 of P-C and Q37 of statherin were the principal reactive residues.	arginyl-glutamine	61-70	statherin	Homo sapiens	216-225
31871199-5	2020	Here we use lysine-to-glutamine mutations as acetylmimetics to map the relevant lysines on actin for INF2 regulation, focusing on K50, K61, and K328.	arginyl-glutamine	22-31	inverted formin 2	Homo sapiens	101-105
31638822-8	2020	One or two secondary glutamine residues of only P-H, P-D P32, P-C and statherin were hierarchically susceptible to the reaction with monodansyl-cadaverine.	arginyl-glutamine	21-30	statherin	Homo sapiens	48-79
31900165-7	2020	We demonstrate that IL-1beta leads to glutamate-induced rod photoreceptor cell death as it increases the extracellular glutamate concentrations in the retina through the inhibition of its conversion to glutamine in Muller cells, increased release from Muller cells, and diminished reuptake.	arginyl-glutamine	202-211	interleukin 1 beta	Homo sapiens	20-28
31685549-0	2020	Anabolic SIRT4 exerts retrograde control over TORC1 signalling by glutamine sparing in the mitochondria.	arginyl-glutamine	66-75	sirtuin 4	Homo sapiens	9-14
31685549-0	2020	Anabolic SIRT4 exerts retrograde control over TORC1 signalling by glutamine sparing in the mitochondria.	arginyl-glutamine	66-75	CREB regulated transcription coactivator 1	Homo sapiens	46-51
31900092-1	2022	Background: Glutamine synthetase (GS) is the only enzyme known to synthesize significant amounts of glutamine in mammals, and loss of GS in the hippocampus has been implicated in the pathophysiology of medication refractory mesial temporal lobe epilepsy (MTLE).	arginyl-glutamine	100-109	glutamate-ammonia ligase	Homo sapiens	12-32
31685549-2	2020	Although, glutamine is known to activate mTOR, if/how differential mitochondrial utilization of glutamine impinges on mTOR signalling is less explored.	arginyl-glutamine	10-19	mechanistic target of rapamycin kinase	Homo sapiens	41-45
31900092-1	2022	Background: Glutamine synthetase (GS) is the only enzyme known to synthesize significant amounts of glutamine in mammals, and loss of GS in the hippocampus has been implicated in the pathophysiology of medication refractory mesial temporal lobe epilepsy (MTLE).	arginyl-glutamine	100-109	glutamate-ammonia ligase	Homo sapiens	34-36
31900092-2	2022	Moreover, loss-of-function mutations of the GS gene causes severe epileptic encephalopathy, and supplementation with glutamine has been shown to normalize EEG and possibly improve the outcome in these patients.	arginyl-glutamine	117-126	glutamate-ammonia ligase	Homo sapiens	44-46
31685549-2	2020	Although, glutamine is known to activate mTOR, if/how differential mitochondrial utilization of glutamine impinges on mTOR signalling is less explored.	arginyl-glutamine	96-105	mechanistic target of rapamycin kinase	Homo sapiens	118-122
31685549-3	2020	Mitochondrial SIRT4, which unlike other sirtuins is induced in a fed state, is known to inhibit catabolic signalling/pathways through AMPK-PGC1alpha/SIRT1-PPARalpha axis and negatively regulate glutamine metabolism via TCA cycle.	arginyl-glutamine	194-203	sirtuin 4	Homo sapiens	14-19
31685549-6	2020	Mechanistically, we demonstrate that the ability of SIRT4 to inhibit anaplerotic conversion of glutamine to alpha-ketoglutarate potentiates TORC1.	arginyl-glutamine	95-104	sirtuin 4	Homo sapiens	52-57
31685549-6	2020	Mechanistically, we demonstrate that the ability of SIRT4 to inhibit anaplerotic conversion of glutamine to alpha-ketoglutarate potentiates TORC1.	arginyl-glutamine	95-104	CREB regulated transcription coactivator 1	Homo sapiens	140-145
31613799-5	2020	The rate-limiting enzyme of the pathway, glutamine-fructose amidotransferase (GFAT1), uses glutamine and fructose 6-phosphate to eventually synthesize UDP-GlcNAc.	arginyl-glutamine	41-50	glutamine--fructose-6-phosphate transaminase 1	Homo sapiens	78-83
31685549-7	2020	Interestingly, we also show that mitochondrial glutamine sparing or utilization is critical for differentially regulating TORC1 under fed and fasted conditions.	arginyl-glutamine	47-56	CREB regulated transcription coactivator 1	Homo sapiens	122-127
31685549-8	2020	Moreover, we conclusively show that differential expression of SIRT4 during fed and fasted states is vital for coupling mitochondrial energetics and glutamine utilization with anabolic pathways.	arginyl-glutamine	149-158	sirtuin 4	Homo sapiens	63-68
31819178-0	2020	ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.	arginyl-glutamine	25-34	solute carrier family 1 member 5	Homo sapiens	0-5
31819178-0	2020	ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.	arginyl-glutamine	25-34	solute carrier family 1 member 5	Homo sapiens	7-13
31819178-5	2020	In this study, ASCT2, an amino acid transporter responsible for glutamine transport, in addition to LAT1 and GLS, is overexpressed in HNSCC and associated with poor survival.	arginyl-glutamine	64-73	solute carrier family 1 member 5	Homo sapiens	15-20
31819178-6	2020	Using both in vivo and in vitro models, we found that knocking down ASCT2 by shRNAs or miR-137 or the combination of silencing ASCT2 and pharmacologically inhibiting SNAT2 via a small-molecule antagonist called V-9302 significantly suppressed intracellular glutamine levels and downstream glutamine metabolism, including glutathione production; these effects attenuated growth and proliferation, increased apoptosis and autophagy, and increased oxidative stress and mTORC1 pathway suppression in HNSCC.	arginyl-glutamine	257-266	solute carrier family 38 member 2	Homo sapiens	166-171
31819178-6	2020	Using both in vivo and in vitro models, we found that knocking down ASCT2 by shRNAs or miR-137 or the combination of silencing ASCT2 and pharmacologically inhibiting SNAT2 via a small-molecule antagonist called V-9302 significantly suppressed intracellular glutamine levels and downstream glutamine metabolism, including glutathione production; these effects attenuated growth and proliferation, increased apoptosis and autophagy, and increased oxidative stress and mTORC1 pathway suppression in HNSCC.	arginyl-glutamine	289-298	solute carrier family 38 member 2	Homo sapiens	166-171
31819178-8	2020	CONCLUSIONS: In summary, ASCT2-dependent glutamine uptake and subsequent glutamine metabolism are essential for HNSCC tumorigenesis, and the combination of glutamine uptake inhibitors and cetuximab presents a promising strategy for improving the outcomes of HNSCC patients.	arginyl-glutamine	41-50	solute carrier family 1 member 5	Homo sapiens	25-30
31819178-8	2020	CONCLUSIONS: In summary, ASCT2-dependent glutamine uptake and subsequent glutamine metabolism are essential for HNSCC tumorigenesis, and the combination of glutamine uptake inhibitors and cetuximab presents a promising strategy for improving the outcomes of HNSCC patients.	arginyl-glutamine	73-82	solute carrier family 1 member 5	Homo sapiens	25-30
31819178-8	2020	CONCLUSIONS: In summary, ASCT2-dependent glutamine uptake and subsequent glutamine metabolism are essential for HNSCC tumorigenesis, and the combination of glutamine uptake inhibitors and cetuximab presents a promising strategy for improving the outcomes of HNSCC patients.	arginyl-glutamine	73-82	solute carrier family 1 member 5	Homo sapiens	25-30
31709772-3	2020	Alanine-serine-cysteine transporter 2 (ASCT2) is a primary transporter for glutamine in cancer cells.	arginyl-glutamine	75-84	solute carrier family 1 member 5	Homo sapiens	39-44
31881361-11	2020	In fibrotic livers, Gls2 nearly disappeared and GS zonality was lost, but both Slc1a5 (glutamine transporter) and kidney-type Gls1 were up-regulated; Gls1 protein was restricted to stromal cells and accumulated in fibrotic septa.	arginyl-glutamine	87-96	solute carrier family 1 (neutral amino acid transporter), member 5	Mus musculus	79-85
32072901-3	2020	This review focuses on the effects of amino acids (arginine, branched-chain amino acids, glutamine) and their metabolites (short chain fatty acids) on glycolipid metabolism by regulating PI3K/AKT/mTOR and AMPK signaling pathways and GPCRs receptors, reducing intestinal Firmicutes/Bacteroidetes ratio associated with obesity.	arginyl-glutamine	89-98	AKT serine/threonine kinase 1	Homo sapiens	192-195
32072901-3	2020	This review focuses on the effects of amino acids (arginine, branched-chain amino acids, glutamine) and their metabolites (short chain fatty acids) on glycolipid metabolism by regulating PI3K/AKT/mTOR and AMPK signaling pathways and GPCRs receptors, reducing intestinal Firmicutes/Bacteroidetes ratio associated with obesity.	arginyl-glutamine	89-98	mechanistic target of rapamycin kinase	Homo sapiens	196-200
31957859-13	2020	Additionally, IR group had significantly elevated expression levels of TNF-alpha and IL-6 compared with the sham group (p<0.01), whereas the IR+Gln group had notably decreased expression levels of TNF-alpha and IL-6 compared with IR group (p<0.05).	arginyl-glutamine	147-150	interleukin 6	Rattus norvegicus	214-218
31650666-5	2020	Under nitrogen-limited stress, regardless of the preferred nitrogen (glutamine, Gln) or non-preferred nitrogen (proline, Pro), 70% of Gat1 in the cells was located in the nucleus-cytoplasm, which resulted in an increase in nitrogen uptake and PMA biosynthesis regulation.	arginyl-glutamine	69-78	solute carrier family 6 member 1	Homo sapiens	134-138
31957859-0	2020	Glutamine protects myocardial ischemia-reperfusion injury in rats through the PI3K/Akt signaling pathway.	arginyl-glutamine	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	83-86
31957859-1	2020	OBJECTIVE: To study the protective mechanism of glutamine (Gln) on myocardial ischemia-reperfusion (IR) injury in rats through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.	arginyl-glutamine	48-57	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	131-160
31957859-16	2020	CONCLUSIONS: Gln activates the PI3K/Akt signaling pathway by increasing the levels of p-AKT and p-mTOR.	arginyl-glutamine	13-16	AKT serine/threonine kinase 1	Homo sapiens	36-39
31957859-1	2020	OBJECTIVE: To study the protective mechanism of glutamine (Gln) on myocardial ischemia-reperfusion (IR) injury in rats through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.	arginyl-glutamine	48-57	AKT serine/threonine kinase 1	Rattus norvegicus	186-189
31957859-17	2020	Gln can increase the PCNA level and reduce the P21 level, so as to enhance the proliferation ability of cardiomyocytes.	arginyl-glutamine	0-3	proliferating cell nuclear antigen	Homo sapiens	21-25
31957859-1	2020	OBJECTIVE: To study the protective mechanism of glutamine (Gln) on myocardial ischemia-reperfusion (IR) injury in rats through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.	arginyl-glutamine	59-62	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	131-160
31957859-17	2020	Gln can increase the PCNA level and reduce the P21 level, so as to enhance the proliferation ability of cardiomyocytes.	arginyl-glutamine	0-3	H3 histone pseudogene 16	Homo sapiens	47-50
31957859-10	2020	In comparison with those in the IR group, ratios of p-AKT/AKT, p-mTOR/mTOR, and the level of PCNA were remarkably raised, while the level of P21 was remarkably reduced in IR+Gln group (p<0.05).	arginyl-glutamine	174-177	mechanistic target of rapamycin kinase	Homo sapiens	65-69
31957859-10	2020	In comparison with those in the IR group, ratios of p-AKT/AKT, p-mTOR/mTOR, and the level of PCNA were remarkably raised, while the level of P21 was remarkably reduced in IR+Gln group (p<0.05).	arginyl-glutamine	174-177	proliferating cell nuclear antigen	Homo sapiens	93-97
31957859-18	2020	Besides, Gln reduces the levels of inflammatory cytokines, TNF-alpha, and IL-6, and inhibits cell apoptosis.	arginyl-glutamine	9-12	tumor necrosis factor	Rattus norvegicus	59-68
31957859-10	2020	In comparison with those in the IR group, ratios of p-AKT/AKT, p-mTOR/mTOR, and the level of PCNA were remarkably raised, while the level of P21 was remarkably reduced in IR+Gln group (p<0.05).	arginyl-glutamine	174-177	H3 histone pseudogene 16	Homo sapiens	141-144
31957859-18	2020	Besides, Gln reduces the levels of inflammatory cytokines, TNF-alpha, and IL-6, and inhibits cell apoptosis.	arginyl-glutamine	9-12	interleukin 6	Rattus norvegicus	74-78
31957859-13	2020	Additionally, IR group had significantly elevated expression levels of TNF-alpha and IL-6 compared with the sham group (p<0.01), whereas the IR+Gln group had notably decreased expression levels of TNF-alpha and IL-6 compared with IR group (p<0.05).	arginyl-glutamine	147-150	tumor necrosis factor	Rattus norvegicus	200-209
31957859-19	2020	Finally, Gln can protect cells from myocardial IR injury by activating the PI3K/Akt signaling pathway.	arginyl-glutamine	9-12	AKT serine/threonine kinase 1	Homo sapiens	80-83
31914648-5	2020	However, due to the block in the TCA cycle at SDH, the high glutamine oxidation activity is only maintained through an efflux of succinate.	arginyl-glutamine	60-69	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	46-49
32021249-2	2019	Transported by SLC1A5, a Na+ dependent transporter, glutamine is absorbed for further use.	arginyl-glutamine	52-61	solute carrier family 1 member 5	Homo sapiens	15-21
31933415-4	2020	Enhanced glycolysis and glutamine-driven tricarboxylic acid cycle have been proven to be important metabolic pathways for trained immunity induced by BCG, which is dependent on Akt/mTOR pathway.	arginyl-glutamine	24-33	AKT serine/threonine kinase 1	Homo sapiens	177-180
31933415-4	2020	Enhanced glycolysis and glutamine-driven tricarboxylic acid cycle have been proven to be important metabolic pathways for trained immunity induced by BCG, which is dependent on Akt/mTOR pathway.	arginyl-glutamine	24-33	mechanistic target of rapamycin kinase	Homo sapiens	181-185
31541193-6	2020	In several cell lines, GLS2 knockdown decreased cell proliferation and glutamine-linked metabolic phenotypes.	arginyl-glutamine	71-80	glutaminase 2	Homo sapiens	23-27
31696233-1	2020	Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by abnormal expansion of glutamine (Q) encoding CAG repeats in the gene Ataxin-1 (ATXN1).	arginyl-glutamine	106-115	ataxin 1	Mus musculus	0-29
31696233-1	2020	Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by abnormal expansion of glutamine (Q) encoding CAG repeats in the gene Ataxin-1 (ATXN1).	arginyl-glutamine	106-115	ataxin 1	Mus musculus	31-35
31696233-1	2020	Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by abnormal expansion of glutamine (Q) encoding CAG repeats in the gene Ataxin-1 (ATXN1).	arginyl-glutamine	106-115	ataxin 1	Mus musculus	153-161
31696233-1	2020	Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by abnormal expansion of glutamine (Q) encoding CAG repeats in the gene Ataxin-1 (ATXN1).	arginyl-glutamine	106-115	ataxin 1	Mus musculus	163-168
31866300-1	2020	Imported across the plasma membrane by SLC1A5, glutamine has emerged as a metabolic fuel that is catabolized by mitochondrial glutaminase to support tumor growth.	arginyl-glutamine	47-56	solute carrier family 1 member 5	Homo sapiens	39-45
31866300-2	2020	The missing link between cytoplasmic and mitochondrial glutamine metabolism is now provided by Yoo et al., identifying the mitochondrial glutamine importer as a variant of SLC1A5.	arginyl-glutamine	55-64	solute carrier family 1 member 5	Homo sapiens	172-178
31866300-2	2020	The missing link between cytoplasmic and mitochondrial glutamine metabolism is now provided by Yoo et al., identifying the mitochondrial glutamine importer as a variant of SLC1A5.	arginyl-glutamine	137-146	solute carrier family 1 member 5	Homo sapiens	172-178
32021249-9	2019	Berberine suppressed the glutamine uptake by inhibiting SLC1A5.	arginyl-glutamine	25-34	solute carrier family 1 member 5	Homo sapiens	56-62
32021249-10	2019	The upregulation of SLC1A5 led to an increased glutamine uptake and improved tolerance to berberine.	arginyl-glutamine	47-56	solute carrier family 1 member 5	Homo sapiens	20-26
31843902-4	2019	In transformed cells, SIRT5 regulates glutamine metabolism by desuccinylating GLS and thereby protecting it from ubiquitin-mediated degradation.	arginyl-glutamine	38-47	sirtuin 5	Homo sapiens	22-27
31849453-0	2019	The Effect of Glutamine Supplementation on Oxidative Stress and Matrix Metalloproteinase 2 and 9 After Exhaustive Exercise.	arginyl-glutamine	14-23	matrix metallopeptidase 2	Homo sapiens	64-90
31844152-4	2019	Consistent with our prior observation that colorectal cancers (CRCs) with oncogenic mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic (PIK3CA) subunit are more dependent on glutamine than CRCs with wild type PIK3CA, labeling from glutamine to most TCA cycle intermediates was higher in PIK3CA-mutant subcutaneous xenograft tumors than in wild type PIK3CA tumors.	arginyl-glutamine	197-206	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	159-165
31844152-4	2019	Consistent with our prior observation that colorectal cancers (CRCs) with oncogenic mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic (PIK3CA) subunit are more dependent on glutamine than CRCs with wild type PIK3CA, labeling from glutamine to most TCA cycle intermediates was higher in PIK3CA-mutant subcutaneous xenograft tumors than in wild type PIK3CA tumors.	arginyl-glutamine	254-263	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	159-165
31849453-3	2019	The present study was conducted to investigate the effect of glutamine supplementation on oxidative stress and matrix metalloproteinase 2 and 9 after exhaustive exercise in young healthy males.	arginyl-glutamine	61-70	matrix metallopeptidase 2	Homo sapiens	111-137
31849453-14	2019	Conclusion: Results of this study showed that, some biochemical factors are time-dependent and can increase or decrease over time, as well as, serum levels of hs-CRP and MDA decreased with glutamine supplementation along with the increase in the TAC serum levels, but this supplementation had no effect on serum levels of MMP2 and MMP9 in exhaustive exercise.	arginyl-glutamine	189-198	matrix metallopeptidase 2	Homo sapiens	322-326
31849453-14	2019	Conclusion: Results of this study showed that, some biochemical factors are time-dependent and can increase or decrease over time, as well as, serum levels of hs-CRP and MDA decreased with glutamine supplementation along with the increase in the TAC serum levels, but this supplementation had no effect on serum levels of MMP2 and MMP9 in exhaustive exercise.	arginyl-glutamine	189-198	matrix metallopeptidase 9	Homo sapiens	331-335
31661119-0	2019	Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis.	arginyl-glutamine	0-9	signal transducer and activator of transcription 3	Homo sapiens	70-75
31826641-0	2019	Impairment of Myocardial Glutamine Homeostasis Induced By Suppression of the Amino Acid Carrier SLC1A5 in Failing Myocardium.	arginyl-glutamine	25-34	solute carrier family 1 member 5	Homo sapiens	96-102
31804603-6	2019	In addition, proteasomal inhibition lowered the expression of the glutaminases GLS and GLS2, which support glutamine metabolism and the maintenance of the redox balance.	arginyl-glutamine	107-116	glutaminase 2	Homo sapiens	87-91
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 1 member 5	Homo sapiens	64-69
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 1 member 5	Homo sapiens	71-77
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 7 member 5	Homo sapiens	80-84
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 7 member 5	Homo sapiens	86-92
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 38 member 1	Homo sapiens	95-100
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 38 member 1	Homo sapiens	102-109
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 38 member 2	Homo sapiens	123-130
31694921-2	2019	Here, in studying the recycling of human glutamine transporters ASCT2 (SLC1A5), LAT1 (SLC7A5), SNAT1 (SLC38A1), and SNAT2 (SLC38A2), we establish that following amino acid restriction, the adaptive delivery of SNAT2 to the cell surface relies on retromer, a master conductor of endosomal recycling.	arginyl-glutamine	41-50	solute carrier family 38 member 2	Homo sapiens	210-215
31694921-3	2019	Upon complete amino acid starvation or selective glutamine depletion, we establish that retromer expression is upregulated by transcription factor EB (TFEB) and other members of the MiTF/TFE family of transcription factors through association with CLEAR elements in the promoters of the retromer genes VPS35 and VPS26A TFEB regulation of retromer expression therefore supports adaptive nutrient acquisition through endosomal recycling.	arginyl-glutamine	49-58	transcription factor EB	Homo sapiens	151-155
31694921-3	2019	Upon complete amino acid starvation or selective glutamine depletion, we establish that retromer expression is upregulated by transcription factor EB (TFEB) and other members of the MiTF/TFE family of transcription factors through association with CLEAR elements in the promoters of the retromer genes VPS35 and VPS26A TFEB regulation of retromer expression therefore supports adaptive nutrient acquisition through endosomal recycling.	arginyl-glutamine	49-58	melanocyte inducing transcription factor	Homo sapiens	182-186
31694921-3	2019	Upon complete amino acid starvation or selective glutamine depletion, we establish that retromer expression is upregulated by transcription factor EB (TFEB) and other members of the MiTF/TFE family of transcription factors through association with CLEAR elements in the promoters of the retromer genes VPS35 and VPS26A TFEB regulation of retromer expression therefore supports adaptive nutrient acquisition through endosomal recycling.	arginyl-glutamine	49-58	VPS35 retromer complex component	Homo sapiens	302-307
31694921-3	2019	Upon complete amino acid starvation or selective glutamine depletion, we establish that retromer expression is upregulated by transcription factor EB (TFEB) and other members of the MiTF/TFE family of transcription factors through association with CLEAR elements in the promoters of the retromer genes VPS35 and VPS26A TFEB regulation of retromer expression therefore supports adaptive nutrient acquisition through endosomal recycling.	arginyl-glutamine	49-58	VPS26, retromer complex component A	Homo sapiens	312-318
31694921-3	2019	Upon complete amino acid starvation or selective glutamine depletion, we establish that retromer expression is upregulated by transcription factor EB (TFEB) and other members of the MiTF/TFE family of transcription factors through association with CLEAR elements in the promoters of the retromer genes VPS35 and VPS26A TFEB regulation of retromer expression therefore supports adaptive nutrient acquisition through endosomal recycling.	arginyl-glutamine	49-58	transcription factor EB	Homo sapiens	319-323
31777560-6	2019	Results determined that all probiotic and glutamine treatments elevated the abnormally decreased BW and occludin levels whilst the abnormal elevated serum AST, ALT, TG, IL-6, TNF-alpha, DAO, endotoxin and D-lactate levels were significantly reduced following chronic ethanol consumption.	arginyl-glutamine	42-51	occludin	Rattus norvegicus	104-112
31777560-6	2019	Results determined that all probiotic and glutamine treatments elevated the abnormally decreased BW and occludin levels whilst the abnormal elevated serum AST, ALT, TG, IL-6, TNF-alpha, DAO, endotoxin and D-lactate levels were significantly reduced following chronic ethanol consumption.	arginyl-glutamine	42-51	interleukin 6	Rattus norvegicus	169-173
31777560-6	2019	Results determined that all probiotic and glutamine treatments elevated the abnormally decreased BW and occludin levels whilst the abnormal elevated serum AST, ALT, TG, IL-6, TNF-alpha, DAO, endotoxin and D-lactate levels were significantly reduced following chronic ethanol consumption.	arginyl-glutamine	42-51	tumor necrosis factor	Rattus norvegicus	175-184
31777560-6	2019	Results determined that all probiotic and glutamine treatments elevated the abnormally decreased BW and occludin levels whilst the abnormal elevated serum AST, ALT, TG, IL-6, TNF-alpha, DAO, endotoxin and D-lactate levels were significantly reduced following chronic ethanol consumption.	arginyl-glutamine	42-51	amine oxidase, copper containing 1	Rattus norvegicus	186-189
31661119-6	2019	Importantly, extracellular Gln deprivation deregulated the production of the transcription factor, STAT3.	arginyl-glutamine	27-30	signal transducer and activator of transcription 3	Homo sapiens	99-104
31661119-7	2019	Additionally, STAT3 expression was affected by the degree of Gln metabolism, as regulated by Gln intermediates and ROS.	arginyl-glutamine	61-64	signal transducer and activator of transcription 3	Homo sapiens	14-19
31661119-7	2019	Additionally, STAT3 expression was affected by the degree of Gln metabolism, as regulated by Gln intermediates and ROS.	arginyl-glutamine	93-96	signal transducer and activator of transcription 3	Homo sapiens	14-19
31661119-8	2019	Thus, on the whole, the findings of this study demonstrate that Gln promotes the proliferation of the Gln-dependent bladder cancer cell line, T24, by supplementing adenosine triphosphate (ATP) production and neutralizing ROS to activate the STAT3 pathway.	arginyl-glutamine	64-67	signal transducer and activator of transcription 3	Homo sapiens	241-246
31661119-8	2019	Thus, on the whole, the findings of this study demonstrate that Gln promotes the proliferation of the Gln-dependent bladder cancer cell line, T24, by supplementing adenosine triphosphate (ATP) production and neutralizing ROS to activate the STAT3 pathway.	arginyl-glutamine	102-105	signal transducer and activator of transcription 3	Homo sapiens	241-246
31645751-0	2019	Author Correction: MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.	arginyl-glutamine	71-80	solute carrier family 16 member 7	Homo sapiens	19-23
31645751-0	2019	Author Correction: MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.	arginyl-glutamine	71-80	myelin oligodendrocyte glycoprotein	Homo sapiens	95-98
31666638-0	2019	UGCG influences glutamine metabolism of breast cancer cells.	arginyl-glutamine	16-25	UDP-glucose ceramide glucosyltransferase	Homo sapiens	0-4
31670074-5	2019	Unexpectedly, we discovered that MYCN-amplified cells showed de novo glutamine synthesis.	arginyl-glutamine	69-78	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	33-37
31819487-7	2019	In the PDHA1 KO cells, the glycolysis and the consumption of glucose and glutamine were significantly enhanced, while the OXPHOS was significantly suppressed, implying Warburg effect in the PDHA1 KO cells.	arginyl-glutamine	73-82	pyruvate dehydrogenase E1 subunit alpha 1	Homo sapiens	7-12
31727983-3	2019	Hence, we developed a fully human expression system based on HEK293 cells for the stable and high titer production of recombinant proteins by first knocking out GLUL (encoding glutamine synthetase) using CRISPR-Cas9 system.	arginyl-glutamine	176-185	glutamate-ammonia ligase	Homo sapiens	161-165
31685994-0	2019	CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth.	arginyl-glutamine	58-67	CD9 antigen	Mus musculus	0-3
31685994-7	2019	Mechanistically, CD9 promoted the plasma membrane localization of the glutamine transporter ASCT2, enhancing glutamine uptake in PDAC cells.	arginyl-glutamine	70-79	CD9 antigen	Mus musculus	17-20
31685994-7	2019	Mechanistically, CD9 promoted the plasma membrane localization of the glutamine transporter ASCT2, enhancing glutamine uptake in PDAC cells.	arginyl-glutamine	70-79	solute carrier family 1 (neutral amino acid transporter), member 5	Mus musculus	92-97
31685994-7	2019	Mechanistically, CD9 promoted the plasma membrane localization of the glutamine transporter ASCT2, enhancing glutamine uptake in PDAC cells.	arginyl-glutamine	109-118	CD9 antigen	Mus musculus	17-20
31685994-7	2019	Mechanistically, CD9 promoted the plasma membrane localization of the glutamine transporter ASCT2, enhancing glutamine uptake in PDAC cells.	arginyl-glutamine	109-118	solute carrier family 1 (neutral amino acid transporter), member 5	Mus musculus	92-97
31666638-3	2019	We investigated the influence of UGCG overexpression on glutamine metabolism in breast cancer cells.	arginyl-glutamine	56-65	UDP-glucose ceramide glucosyltransferase	Homo sapiens	33-37
31666638-6	2019	Augmented glutamine uptake is also used for fueling the tricarboxylic acid (TCA) cycle to maintain the proliferative advantage of UGCG overexpressing cells.	arginyl-glutamine	10-19	UDP-glucose ceramide glucosyltransferase	Homo sapiens	130-134
31709262-1	2019	The human SLC1A5 commonly known as ASCT2 is a sodium-dependent neutral amino acid antiporter involved in transmembrane traffic of glutamine that is exchanged through the cell membrane with smaller amino acids such as serine or threonine.	arginyl-glutamine	130-139	solute carrier family 1 member 5	Homo sapiens	10-16
31659213-10	2019	Finally, functionally higher stemness-associated hMSC showed metabolic plasticity when challenged by glucose or glutamine shortage, which mimic bioenergetics switches that hMSC must undergo after transplantation or during self-renewal and differentiation.	arginyl-glutamine	112-121	musculin	Homo sapiens	49-53
31709262-1	2019	The human SLC1A5 commonly known as ASCT2 is a sodium-dependent neutral amino acid antiporter involved in transmembrane traffic of glutamine that is exchanged through the cell membrane with smaller amino acids such as serine or threonine.	arginyl-glutamine	130-139	solute carrier family 1 member 5	Homo sapiens	35-40
31652551-5	2019	GLS2 down-regulation was correlated with reduced mitochondrial activity and glutamine independence even in low-glucose conditions.	arginyl-glutamine	76-85	glutaminase 2	Homo sapiens	0-4
31652551-6	2019	Restoration of GLS2 expression in GLS2-negative breast cancer cells rescued mitochondrial activity, enhanced glutamine utilization, and inhibited stem-cell properties.	arginyl-glutamine	109-118	glutaminase 2	Homo sapiens	15-19
31652551-0	2019	The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression.	arginyl-glutamine	50-59	glutaminase 2	Homo sapiens	88-92
31652551-6	2019	Restoration of GLS2 expression in GLS2-negative breast cancer cells rescued mitochondrial activity, enhanced glutamine utilization, and inhibited stem-cell properties.	arginyl-glutamine	109-118	glutaminase 2	Homo sapiens	34-38
31652551-7	2019	Additionally, inhibition of expression of the transcription factor FOXC2, a critical regulator of EMT in GLS2-negative cells, restored GLS2 expression and glutamine utilization.	arginyl-glutamine	155-164	forkhead box C2	Homo sapiens	67-72
31652551-7	2019	Additionally, inhibition of expression of the transcription factor FOXC2, a critical regulator of EMT in GLS2-negative cells, restored GLS2 expression and glutamine utilization.	arginyl-glutamine	155-164	glutaminase 2	Homo sapiens	105-109
31580259-0	2019	Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.	arginyl-glutamine	32-41	solute carrier family 1 member 5	Homo sapiens	54-60
31578313-2	2019	In addition to blocking EGFR-stimulated cell signaling, cetuximab can induce endocytosis of ASCT2, a glutamine transporter associated with EGFR in a complex, leading to glutathione biosynthesis inhibition and cellular sensitization to ROS.	arginyl-glutamine	101-110	solute carrier family 1 member 5	Homo sapiens	92-97
31580259-0	2019	Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.	arginyl-glutamine	32-41	solute carrier family 1 member 5	Homo sapiens	62-67
31578313-2	2019	In addition to blocking EGFR-stimulated cell signaling, cetuximab can induce endocytosis of ASCT2, a glutamine transporter associated with EGFR in a complex, leading to glutathione biosynthesis inhibition and cellular sensitization to ROS.	arginyl-glutamine	101-110	epidermal growth factor receptor	Homo sapiens	139-143
31580259-1	2019	Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway.	arginyl-glutamine	84-93	solute carrier family 1 member 5	Homo sapiens	0-37
31580259-1	2019	Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway.	arginyl-glutamine	84-93	solute carrier family 1 member 5	Homo sapiens	39-44
31580259-1	2019	Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway.	arginyl-glutamine	84-93	solute carrier family 1 member 5	Homo sapiens	46-52
31580259-1	2019	Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway.	arginyl-glutamine	84-93	CREB regulated transcription coactivator 1	Mus musculus	128-134
31577958-3	2019	Here, by comprehensive metabolome analyses, we show that glutamine deprivation leads to phosphoethanolamine (PEtn) accumulation in cancer cells via the downregulation of PEtn cytidylyltransferase (PCYT2), a rate-limiting enzyme of phosphatidylethanolamine biosynthesis.	arginyl-glutamine	57-66	phosphate cytidylyltransferase 2, ethanolamine	Homo sapiens	197-202
31581742-6	2019	Knockdown of Nrf2 promoted a mesenchymal phenotype and reduced glycolytic, TCA cycle and lipogenic output from both glucose and glutamine in the isogenic cell models; while overexpression of Nrf2 promoted a more epithelial phenotype and metabolic reactivation.	arginyl-glutamine	128-137	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
31577958-8	2019	Thus, we show that glutamine deprivation leads to tumor progression by regulating PE biosynthesis via the ELF3-PCYT2 axis.	arginyl-glutamine	19-28	E74 like ETS transcription factor 3	Homo sapiens	106-110
31577958-8	2019	Thus, we show that glutamine deprivation leads to tumor progression by regulating PE biosynthesis via the ELF3-PCYT2 axis.	arginyl-glutamine	19-28	phosphate cytidylyltransferase 2, ethanolamine	Homo sapiens	111-116
31554283-0	2019	Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism.	arginyl-glutamine	29-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	56-60
31554283-5	2019	Under normoxic conditions, HIF1 activity was significantly increased by (i) glutamine metabolism, which was associated with the release of ammonium, and it was decreased by (ii) acetylation via acetyl CoA synthetase (ACSS2) or ATP citrate lyase (ACLY), respectively, and (iii) the presence of L-ascorbic acid, citrate, or acetyl-CoA.	arginyl-glutamine	76-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	27-31
31611919-4	2019	The integrated mechanism consisting of WNT, mammalian target of rapamycin (mTOR), and reactive oxygen species (ROS) signaling pathway in a glutamine-dependent pattern is responsible to regulate the complex intrinsic biological process, despite more extensive molecules are deserved to be elucidated in glutamine metabolism further.	arginyl-glutamine	139-148	mechanistic target of rapamycin kinase	Homo sapiens	44-73
31687652-5	2019	MSG supplementation, at 5, 10, and 20 g/kg of diet, and PTH injection, used as a positive control, were able to improve BMD and to increase osteoblast activity markers (P1NP and osteocalcin), as well as glutamine plasma concentration.	arginyl-glutamine	203-212	parathyroid hormone	Mus musculus	56-59
31686854-1	2019	Background/aims: 2-oxoglutarate dehydrogenase (OGDH) is the first rate-limiting E1 subunit of OGDH complex (OGDHC), which plays as a regulatory point in the cross-road of TCA cycle and glutamine metabolism.	arginyl-glutamine	185-194	oxoglutarate dehydrogenase	Homo sapiens	17-45
31686854-1	2019	Background/aims: 2-oxoglutarate dehydrogenase (OGDH) is the first rate-limiting E1 subunit of OGDH complex (OGDHC), which plays as a regulatory point in the cross-road of TCA cycle and glutamine metabolism.	arginyl-glutamine	185-194	oxoglutarate dehydrogenase	Homo sapiens	47-51
31686854-1	2019	Background/aims: 2-oxoglutarate dehydrogenase (OGDH) is the first rate-limiting E1 subunit of OGDH complex (OGDHC), which plays as a regulatory point in the cross-road of TCA cycle and glutamine metabolism.	arginyl-glutamine	185-194	oxoglutarate dehydrogenase	Homo sapiens	94-98
31571981-4	2019	Glutaminase (GLS) is the enzyme that mediates the conversion of glutamine to glutamate and has been shown to be upregulated in many cancer types including malignancies of the breast.	arginyl-glutamine	64-73	glutaminase	Homo sapiens	0-11
31571981-4	2019	Glutaminase (GLS) is the enzyme that mediates the conversion of glutamine to glutamate and has been shown to be upregulated in many cancer types including malignancies of the breast.	arginyl-glutamine	64-73	glutaminase	Homo sapiens	13-16
31611919-4	2019	The integrated mechanism consisting of WNT, mammalian target of rapamycin (mTOR), and reactive oxygen species (ROS) signaling pathway in a glutamine-dependent pattern is responsible to regulate the complex intrinsic biological process, despite more extensive molecules are deserved to be elucidated in glutamine metabolism further.	arginyl-glutamine	139-148	mechanistic target of rapamycin kinase	Homo sapiens	75-79
31612309-11	2019	Plasma glutamine levels improved more in glutamine-treated group (432.72 +- 307.83 vs. 618.06 +- 543.29 muM/L; p = 0.004), while it was lower in controls (576.90 +- 477.97 vs. 528.20 +- 410.45 muM/L; p = 0.003).	arginyl-glutamine	7-16	latexin	Homo sapiens	104-107
31636962-4	2019	There were controversial reports on whether human N6amt1, which was originally reported as a glutamine MTase for eRF1, is a putative 6mA DNA MTase.	arginyl-glutamine	93-102	N-6 adenine-specific DNA methyltransferase 1	Homo sapiens	50-56
31636962-4	2019	There were controversial reports on whether human N6amt1, which was originally reported as a glutamine MTase for eRF1, is a putative 6mA DNA MTase.	arginyl-glutamine	93-102	eukaryotic translation termination factor 1	Homo sapiens	113-117
31612309-11	2019	Plasma glutamine levels improved more in glutamine-treated group (432.72 +- 307.83 vs. 618.06 +- 543.29 muM/L; p = 0.004), while it was lower in controls (576.90 +- 477.97 vs. 528.20 +- 410.45 muM/L; p = 0.003).	arginyl-glutamine	41-50	latexin	Homo sapiens	104-107
31612309-11	2019	Plasma glutamine levels improved more in glutamine-treated group (432.72 +- 307.83 vs. 618.06 +- 543.29 muM/L; p = 0.004), while it was lower in controls (576.90 +- 477.97 vs. 528.20 +- 410.45 muM/L; p = 0.003).	arginyl-glutamine	41-50	latexin	Homo sapiens	193-196
31612309-13	2019	Statistically significant reduction in IL-6 concentration was observed in the glutamine group at the end of treatment (87.44 +- 7.1 vs. 63.42 +- 33.7 muM/L; p = 0.02).	arginyl-glutamine	78-87	interleukin 6	Homo sapiens	39-43
31612309-13	2019	Statistically significant reduction in IL-6 concentration was observed in the glutamine group at the end of treatment (87.44 +- 7.1 vs. 63.42 +- 33.7 muM/L; p = 0.02).	arginyl-glutamine	78-87	latexin	Homo sapiens	150-153
23044165-7	2012	RESULTS: The Arg-Gln and DHA prevented the development of key markers of injury, including histologic changes, myeloperoxidase, lactate dehydrogenase, and inflammatory cytokines interleukin-6 and C-X-C motif ligand 1 (CXCL1)/keratinocyte-derived chemokine (KC).	arginyl-glutamine	13-20	myeloperoxidase	Mus musculus	111-126
31939163-1	2019	CAD is a 1.5 MDa particle formed by hexameric association of a 250 kDa protein that carries the enzymatic activities for the first three steps in the de novo biosynthesis of pyrimidine nucleotides: glutamine-dependent Carbamoyl phosphate synthetase, Aspartate transcarbamoylase and Dihydroorotase.	arginyl-glutamine	198-207	aconitate decarboxylase 1	Homo sapiens	0-3
23096083-6	2013	Overall, there was a significant association between XRCC1 Arg399Gln polymorphism and glioma risk in two genetic models (for ArgGln vs ArgArg: OR = 1.30, 95 % CI 1.01-1.68; for GlnGln/ArgGln vs ArgArg: OR = 1.28, 95 % CI 1.01-1.62).	arginyl-glutamine	125-131	X-ray repair cross complementing 1	Homo sapiens	53-58
32007996-4	2019	Besides, in earlier work, supplementation with glutamine, a nonessential amino acid, when administered prior to exercise, decreased overnight post-exercise blood glucose in adolescents with long-standing T1D, suggesting that glutamine increased insulin sensitivity or enhanced tissue glucose uptake.	arginyl-glutamine	225-234	insulin	Homo sapiens	245-252
31938290-8	2018	The synthesis of glutamine transporter ASCT2 and B0AT1 was determined.	arginyl-glutamine	17-26	solute carrier family 1 member 5	Rattus norvegicus	39-44
31938290-8	2018	The synthesis of glutamine transporter ASCT2 and B0AT1 was determined.	arginyl-glutamine	17-26	solute carrier family 6 member 19	Rattus norvegicus	49-54
31938290-14	2018	Finally, the synthesis and modification of ASCT2 and B0AT1 are promoted, which ultimately enhances intestinal glutamine transport.	arginyl-glutamine	110-119	solute carrier family 1 member 5	Rattus norvegicus	43-48
31938290-14	2018	Finally, the synthesis and modification of ASCT2 and B0AT1 are promoted, which ultimately enhances intestinal glutamine transport.	arginyl-glutamine	110-119	solute carrier family 6 member 19	Rattus norvegicus	53-58
23044165-7	2012	RESULTS: The Arg-Gln and DHA prevented the development of key markers of injury, including histologic changes, myeloperoxidase, lactate dehydrogenase, and inflammatory cytokines interleukin-6 and C-X-C motif ligand 1 (CXCL1)/keratinocyte-derived chemokine (KC).	arginyl-glutamine	13-20	interleukin 6	Mus musculus	178-191
23044165-7	2012	RESULTS: The Arg-Gln and DHA prevented the development of key markers of injury, including histologic changes, myeloperoxidase, lactate dehydrogenase, and inflammatory cytokines interleukin-6 and C-X-C motif ligand 1 (CXCL1)/keratinocyte-derived chemokine (KC).	arginyl-glutamine	13-20	chemokine (C-X-C motif) ligand 1	Mus musculus	196-216
23044165-7	2012	RESULTS: The Arg-Gln and DHA prevented the development of key markers of injury, including histologic changes, myeloperoxidase, lactate dehydrogenase, and inflammatory cytokines interleukin-6 and C-X-C motif ligand 1 (CXCL1)/keratinocyte-derived chemokine (KC).	arginyl-glutamine	13-20	chemokine (C-X-C motif) ligand 1	Mus musculus	218-223